



Insights Into Advanced Renal Cell Carcinoma (RCC) January 14, 2021

Speaker: Neeraj Agarwal, MD
Moderator: Sushil Bhardwaj, MD, FACP

AGENDA

Time (PT)	Topic
5.00 PM – 5.15 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • ARS questions
5.15 PM – 6.25 PM (25-min presentation; 45-min discussion)	First-Line Therapy of Advanced Renal Cell Carcinoma <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – Selection of approved TKI therapy in first line – Review of differential efficacy, safety, and tolerability across TKIs – Cabozantinib in first vs subsequent line treatment (CABOSUN) – Immunotherapy combinations – Therapy for patients with poor-risk features vs favorable • Reaction and discussion
6.25 PM – 6.35 PM (10 min)	Break
6.35 PM – 7.45 PM (25-min presentation; 45-min discussion)	Subsequent Management of Advanced Renal Cell Carcinoma <ul style="list-style-type: none"> • ARS questions • Overview of current data <ul style="list-style-type: none"> – Impact of first-line therapy on subsequent therapy sequencing – Therapy following initial TKI failure – TKIs vs immunotherapy vs mTOR inhibition (or combinations?) • Reaction and discussion
7.45 PM – 8.00 PM (15 min)	Key Takeaways and Meeting Evaluation